Harness arsenic in medicine: current status of arsenicals and recent advances in drug delivery

References

• Paul NP, Galván AE, Yoshinaga-Sakurai K, et al. Arsenic in medicine: past, present and future. Biomet Int J Role Met Ions Biol Biochem Med. 2023;36(2):283–301. doi: 10.1007/s10534-022-00371-y
   Google Scholar
• Cholujova D, Bujnakova Z, Dutkova E, et al. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017;179(5):756–771. doi: 10.1111/bjh.14974
   PubMed Web of Science ®Google Scholar
• Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89(9):3354–3360. doi: 10.1182/blood.V89.9.3354
   PubMed Web of Science ®Google Scholar
• Gallagher RE. Arsenic — new life for an old potion. N Engl J Med. 1998;339(19):1389–1391. doi: 10.1056/NEJM199811053391909
   PubMed Web of Science ®Google Scholar
• Kwong YL, Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood. 1997;89(9):3487–3487. doi: 10.1182/blood.V89.9.3487
   PubMed Web of Science ®Google Scholar
• Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev. 2007;33(6):542–564. doi: 10.1016/j.ctrv.2007.05.001
   PubMed Web of Science ®Google Scholar
• Khairul I, Wang QQ, Jiang YH, et al. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget. 2017;8(14):23905–23926. doi: 10.18632/oncotarget.14733
   PubMedGoogle Scholar
• Emadi A, Gore SD. Arsenic trioxide — an old drug rediscovered. Blood Rev. 2010;24(4–5):191–199. doi: 10.1016/j.blre.2010.04.001
   PubMed Web of Science ®Google Scholar
• Chen G, Zhu J, Shi X, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996;88(3):1052–1061. doi: 10.1182/blood.V88.3.1052.1052
   PubMed Web of Science ®Google Scholar
• Lallemand-Breitenbach V, de Thé H. PML nuclear bodies: from architecture to function. Curr Opin Cell Biol. 2018;52:154–161. doi: 10.1016/j.ceb.2018.03.011
   PubMed Web of Science ®Google Scholar
• Wang Z-G, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a pml and pml-rar? independent manner. Blood. 1998;92(5):1497–1504. doi: 10.1182/blood.V92.5.1497
   PubMed Web of Science ®Google Scholar
• Ye Y, Gaugler B, Mohty M, et al. Old dog, new trick: trivalent arsenic as an immunomodulatory drug. Br J Pharmacol. 2020;177(10):2199–2214. doi: 10.1111/bph.15011
   PubMed Web of Science ®Google Scholar
• Miller WH, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic trioxide. Cancer Res. 2002;62:3893–3903.
   PubMed Web of Science ®Google Scholar
• Shen S, Li X-F, Cullen WR, et al. Arsenic binding to proteins. Chem Rev. 2013;113(10):7769–7792. doi: 10.1021/cr300015c
   PubMed Web of Science ®Google Scholar
• Mancini I, Defant A. Bioactive Poly(Arsenic) compounds. In: Biomedical Inorganic Polymers: Bioactivity and Applications of Natural and Synthetic Polymeric Inorganic Molecules [Internet]. Berlin Heidelberg: Springer; 2013 Nov 22. p.175–195.
   Google Scholar
• Swindell EP, Hankins PL, Chen H, et al. Anticancer activity of small-molecule and nanoparticulate arsenic(III) complexes. Inorg Chem. 2013;52(21):12292–12304. doi: 10.1021/ic401211u
   PubMed Web of Science ®Google Scholar
• National Research Council (US). Chemistry of Arsenic. In: Arsenic: Medical and Biological Effects of Environmental Pollutants [Internet]. National Academies Press (US); 1977. p. 4–15.
   Google Scholar
• Maranhão RC, Vital CG, Tavoni TM, et al. Clinical experience with drug delivery systems as tools to decrease the toxicity of anticancer chemotherapeutic agents. Expert Opin Drug Deliv. 2017;14(10):1217–1226. doi: 10.1080/17425247.2017.1276560
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang G, Yang H. Drug delivery systems for differential release in combination therapy. Expert Opin Drug Deliv. 2011;8(2):171–190. doi: 10.1517/17425247.2011.547470
   PubMed Web of Science ®Google Scholar
• Gao J, Karp JM, Langer R, et al. The future of drug delivery. Chem Mater. 2023;35(2):359–363. doi: 10.1021/acs.chemmater.2c03003
   PubMed Web of Science ®Google Scholar
• Sönksen M, Kerl K, Bunzen H. Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors. Med Res Rev. 2022;42(1):374–398. doi: 10.1002/med.21844
   PubMed Web of Science ®Google Scholar
• Yu M, Zhang Y, Fang M, et al. Current advances of nanomedicines delivering arsenic trioxide for enhanced tumor therapy. Pharmaceutics. 2022;14(4):743. doi: 10.3390/pharmaceutics14040743
   PubMed Web of Science ®Google Scholar
• Mondal R, Majumdar A, Sarkar S, et al. An extensive review of arsenic dynamics and its distribution in soil-aqueous-rice plant systems in south and Southeast Asia with bibliographic and meta-data analysis. Chemosphere. 2024;352:141460. doi: 10.1016/j.chemosphere.2024.141460
   PubMedGoogle Scholar
• Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncology. 2001;6(S2):3–10. doi: 10.1634/theoncologist.6-suppl_2-3
   Google Scholar
• Liu F, Hooks DE, Li N, et al. Mechanical properties of anhydrous and hydrated uric acid crystals. Chem Mater. 2018;30(11):3798–3805. doi: 10.1021/acs.chemmater.8b00939
   Web of Science ®Google Scholar
• Liu F, Hooks DE, Li N, et al. Molecular crystal mechanical properties altered via dopant inclusion. Chem Mater. 2020;32(9):3952–3959. doi: 10.1021/acs.chemmater.0c00433
   Web of Science ®Google Scholar
• Liu F, Bagi SD, Su Q, et al. Targeting particle size specification in pharmaceutical crystallization: a review on recent process design and development strategies and particle size measurements. Org Process Res Dev. 2022;26(12):3190–3203. doi: 10.1021/acs.oprd.2c00277
   Web of Science ®Google Scholar
• Liu F, Li H, Li Y. Breakage-facilitated mixed-suspension-mixed-product-removal (MSMPR) crystallization of pharmaceutical compounds. Cryst Growth Des. 2024;24(4):1591–1602. doi: 10.1021/acs.cgd.3c01220
   Web of Science ®Google Scholar
• Lin M, Wang Z, Zhang D. Preparation of orpiment nanoparticles and their cytotoxic effect on cultured leukemia k562 cells. J Nanosci Nanotechnol. 2007;7(2):490–496. doi: 10.1166/jnn.2007.145
   PubMed Web of Science ®Google Scholar
• Baláž P, Sedlák J. Arsenic in cancer treatment: challenges for application of realgar nanoparticles (a minireview). Toxins (Basel). 2010;2(6):1568–1581. doi: 10.3390/toxins2061568
   PubMed Web of Science ®Google Scholar
• Liu J, Lu Y, Wu Q, et al. Mineral arsenicals in traditional medicines: orpiment, realgar, and arsenolite. J Pharmacol Exp Ther. 2008;326(2):363–368. doi: 10.1124/jpet.108.139543
   PubMed Web of Science ®Google Scholar
• Wu J-Z, Ho PC. Evaluation of the in vitro activity and in vivo bioavailability of realgar nanoparticles prepared by cryo-grinding. Eur J Pharm Sci. 2006;29(1):35–44. doi: 10.1016/j.ejps.2006.05.002
   PubMed Web of Science ®Google Scholar
• Wu J, Shao Y, Liu J, et al. The medicinal use of realgar (As₄s₄) and its recent development as an anticancer agent. Journal Of Ethnopharmacology. 2011;135(3):595–602. doi: 10.1016/j.jep.2011.03.071
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang J-C, Han Y-H, et al. High expression of bcl-xL in K562 cells and its role in the low sensitivity of K562 to realgar-induced apoptosis. Acta Haematol. 2005;113:247–254. doi: 10.1159/000084678
   PubMed Web of Science ®Google Scholar
• Zhao W, Lu X, Yuan Y, et al. Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines. Int J Nanomedicine. 2011;6:1569–1577. doi: 10.2147/IJN.S21373
   PubMed Web of Science ®Google Scholar
• Wang J, Lin M, Zhang T, et al. Arsenic(ii) sulfide quantum dots prepared by a wet process from its bulk. J Am Chem Soc. 2008;130(35):11596–11597. doi: 10.1021/ja804436w
   PubMed Web of Science ®Google Scholar
• Chen H, MacDonald RC, Li S, et al. Lipid encapsulation of arsenic trioxide attenuates cytotoxicity and allows for controlled anticancer drug release. J Am Chem Soc. 2006;128:13348–13349. doi: 10.1021/ja064864h
   PubMed Web of Science ®Google Scholar
• Ni Dhubhghaill OM, Sadler PJ. The structure and reactivity of arsenic compounds: biological activity and drug design. In: Bioinorganic chemistry [Internet]. Berlin Heidelberg: Springer; 1991. p. 129–190.
   Google Scholar
• Yang H-C, Fu H-L, Lin Y-F, et al. Chapter Twelve - Pathways of Arsenic Uptake and Efflux. In: Argüello J, and Lutsenko S, editors. Current Topics in Membranes. Vol. 69. Academic Press; 2012. p. 325–358.
   Google Scholar
• Liu Z, Shen J, Carbrey JM, et al. Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9. Proc Natl Acad Sci. 2002;99(9):6053–6058. doi: 10.1073/pnas.092131899
   PubMed Web of Science ®Google Scholar
• Liu J, Chen H, Miller DS, et al. Overexpression of glutathione s -transferase ii and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol. 2001;60(2):302–309. doi: 10.1124/mol.60.2.302
   PubMed Web of Science ®Google Scholar
• Jeanne M, Lallemand-Breitenbach V, Ferhi O, Koken M, Le Bras M, Duffort S, et al. PML/RAR oxidation and arsenic binding initiate the antileukemia response of As2O3. Cancer Cell. 2010;18(1):88–98. doi: 10.1016/j.ccr.2010.06.003
   PubMed Web of Science ®Google Scholar
• Ajees AA, Marapakala K, Packianathan C, et al. Structure of an As(iii) s -adenosylmethionine methyltransferase: insights into the mechanism of arsenic biotransformation. Biochemistry. 2012;51(27):5476–5485. doi: 10.1021/bi3004632
   PubMed Web of Science ®Google Scholar
• Platanias LC. Biological responses to arsenic compounds. J Biol Chem. 2009;284(28):18583–18587. doi: 10.1074/jbc.R900003200
   PubMed Web of Science ®Google Scholar
• Lin S, Shi Q, Nix FB, et al. A novel s-adenosyl-l-methionine: arsenic(iii) methyltransferase from rat liver cytosol. J Biol Chem. 2002;277(13):10795–10803. doi: 10.1074/jbc.M110246200
   PubMed Web of Science ®Google Scholar
• Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (mrp1/abcc1): evidence that a tri-glutathione conjugate is required. J Biol Chem. 2004;279(31):32700–32708. doi: 10.1074/jbc.M404912200
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang L, Ling J, et al. Systematic identification of arsenic-binding proteins reveals that hexokinase-2 is inhibited by arsenic. Proc Natl Acad Sci. 2015;112(49):15084–15089. doi: 10.1073/pnas.1521316112
   PubMed Web of Science ®Google Scholar
• Hu X, Li H, Ip T-Y, et al. Arsenic trioxide targets Hsp60, triggering degradation of p53 and survivin. Chem Sci. 2021;12(32):10893–10900. doi: 10.1039/D1SC03119H
   PubMed Web of Science ®Google Scholar
• Hoonjan M, Jadhav V, Bhatt P. Arsenic trioxide: insights into its evolution to an anticancer agent. JBIC J Biol Inorg Chem. 2018;23(3):313–329. doi: 10.1007/s00775-018-1537-9
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett. 1999;455(1–2):59–62. doi: 10.1016/S0014-5793(99)00841-8
   PubMed Web of Science ®Google Scholar
• Jiang X-H, Chun-Yu Wong B, Yuen S-T, et al. Arsenic trioxide induces apoptosis in human gastric cancer cells through up-regulation of P53 and activation of caspase-3. Int J Cancer. 2001;91(2):173–179. doi: 10.1002/1097-0215(200002)9999:9999<:AID-IJC1039>3.0.CO;2-D
   PubMed Web of Science ®Google Scholar
• Park J-W, Choi Y-J, Jang MA, et al. Arsenic trioxide induces G2/M growth arrest and apoptosis after caspase-3 activation and Bcl-2 phosphorylation in Promonocytic U937 Cells. Biochem Biophys Res Commun. 2001;286(4):726–734. doi: 10.1006/bbrc.2001.5416
   PubMed Web of Science ®Google Scholar
• Mahieux R, Pise-Masison C, Gessain A, et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1– and type 2–infected cells by a caspase-3–dependent mechanism involving Bcl-2 cleavage. Blood. 2001;98(13):3762–3769. doi: 10.1182/blood.V98.13.3762
   PubMed Web of Science ®Google Scholar
• Gupta S, Yel L, Kim D, et al. Arsenic trioxide induces apoptosis in peripheral blood t lymphocyte subsets by inducing oxidative stress: a role of bcl-2. Mol Cancer Ther. 2003;2(8):711–719.
   PubMed Web of Science ®Google Scholar
• Liu Q, Hilsenbeck S, Gazitt Y, et al. Arsenic trioxide–induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL: presented in preliminary form at the 43rd annual meeting of the American society of hematology. Blood. 2003 [2001 Dec 8];101(10):4078–4087. doi: 10.1182/blood-2002-10-3231
   PubMedGoogle Scholar
• Xu W, Li X, Quan L, et al. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia. Leuk Lymphoma. 2018;59(3):650–659. doi: 10.1080/10428194.2017.1346253
   PubMed Web of Science ®Google Scholar
• Huang W, Zeng YC. A candidate for lung cancer treatment: arsenic trioxide. Clin Transl Oncol. 2019;21(9):1115–1126. doi: 10.1007/s12094-019-02054-6
   PubMed Web of Science ®Google Scholar
• Zheng Y, Zhou M, Ye A, et al. The conformation change of Bcl-2 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in SGC7901 human gastric cancer cells. World J Surg Oncol. 2010;8(1):31. doi: 10.1186/1477-7819-8-31
   PubMedGoogle Scholar
• Chow SKY, Chan JYW, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004;93:173–187. doi: 10.1002/jcb.20102
   PubMed Web of Science ®Google Scholar
• Oketani M, Kohara K, Tuvdendorj D, et al. Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett. 2002;183(2):147–153. doi: 10.1016/S0304-3835(01)00800-X
   PubMed Web of Science ®Google Scholar
• Miller WH Jr, Schipper HM, Lee JS, et al. Mechanisms of action of arsenic Trioxide1. Cancer Res. 2002;62:3893–3903.
   PubMed Web of Science ®Google Scholar
• Seol JG, Park WH, Kim ES, et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun. 1999;265(2):400–404. doi: 10.1006/bbrc.1999.1697
   PubMed Web of Science ®Google Scholar
• Li X, Ding X, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and Gadd expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest. 2004;22(3):389–400. doi: 10.1081/CNV-200029068
   PubMed Web of Science ®Google Scholar
• Ramos AM, Fernàndez C, Amràn D, et al. Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells. Blood. 2005;105(10):4013–4020. doi: 10.1182/blood-2004-07-2802
   PubMed Web of Science ®Google Scholar
• Chiu H-W, Ho S-Y, Guo H-R, et al. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy. 2009;5(4):472–483. doi: 10.4161/auto.5.4.7759
   PubMed Web of Science ®Google Scholar
• Park WH, Seol JG, Kim ES, et al. Arsenic trioxide-mediated growth inhibition in mc/car myeloma cells via cell cycle arrest in association with induction of cyclin-dependent kinase inhibitor, p21, and apoptosis1. Cancer Res. 2000;60:3065–3071.
   PubMed Web of Science ®Google Scholar
• Hyun Park W, Hee Cho Y, Won Jung C, et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun. 2003;300(1):230–235. doi: 10.1016/S0006-291X(02)02831-0
   PubMed Web of Science ®Google Scholar
• Goussetis DJ, Altman JK, Glaser H, et al. Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide. J Biol Chem. 2010;285:29989–29997. doi: 10.1074/jbc.M109.090530
   PubMed Web of Science ®Google Scholar
• Lau A, Zheng Y, Tao S, et al. Arsenic inhibits autophagic flux, activating the nrf2-keap1 pathway in a p62-dependent manner. Mol Cell Biol. 2013;33(12):2436–2446. doi: 10.1128/MCB.01748-12
   PubMed Web of Science ®Google Scholar
• Fang S, Wan X, Zou X, et al. Arsenic trioxide induces macrophage autophagy and atheroprotection by regulating ROS-dependent TFEB nuclear translocation and AKT/mTOR pathway. Cell Death Dis. 2021;12(1):88. doi: 10.1038/s41419-020-03357-1
   PubMed Web of Science ®Google Scholar
• Liang C, Feng Z, Manthari RK, et al. Arsenic induces dysfunctional autophagy via dual regulation of mTOR pathway and Beclin1-Vps34/PI3K complex in MLTC-1 cells. J Hazard Mater. 2020;391:122227. doi: 10.1016/j.jhazmat.2020.122227
   PubMed Web of Science ®Google Scholar
• Wang G, Zhang T, Sun W, et al. Arsenic sulfide induces apoptosis and autophagy through the activation of ROS/JNK and suppression of Akt/mTOR signaling pathways in osteosarcoma. Free Radic Biol Med. 2017;106:24–37. doi: 10.1016/j.freeradbiomed.2017.02.015
   PubMed Web of Science ®Google Scholar
• Cui Z, Zhang Y, Xia K, et al. Nanodiamond autophagy inhibitor allosterically improves the arsenical-based therapy of solid tumors. Nat Commun. 2018;9(1):4347. doi: 10.1038/s41467-018-06749-2
   PubMedGoogle Scholar
• Sun Z, Li M, Bai L, et al. Arsenic trioxide inhibits angiogenesis in vitro and in vivo by upregulating FoxO3a. Toxicol Lett. 2019;315:1–8. doi: 10.1016/j.toxlet.2019.08.009
   PubMed Web of Science ®Google Scholar
• Zhang L, Liu L, Zhan S, et al. Arsenic trioxide suppressed migration and angiogenesis by targeting FOXO3a in gastric cancer cells. Int J Mol Sci. 2018;19(12):3739. doi: 10.3390/ijms19123739
   PubMed Web of Science ®Google Scholar
• Yancy SL, Shelden EA, Gilmont RR, et al. Sodium arsenite exposure alters cell migration, focal adhesion localization and decreases tyrosine phosphorylation of focal adhesion kinase in H9C2 myoblasts. Toxicological Sciences. 2005;84(2):278–286. doi: 10.1093/toxsci/kfi032
   PubMed Web of Science ®Google Scholar
• Zhang L, Kim S, Ding W, et al. Arsenic sulfide inhibits cell migration and invasion of gastric cancer in vitro and in vivo. Drug Des Devel Ther. 2015;9:5579–5590. doi: 10.2147/DDDT.S89805
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment 1. Mol Cancer Ther. 2002;1:851–860.
   PubMed Web of Science ®Google Scholar
• Chen J, Jin Z, Zhang S, et al. Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. Cell Mol Immunol. 2023;20(1):51–64. doi: 10.1038/s41423-022-00956-0
   PubMed Web of Science ®Google Scholar
• Zhang J, Qin Y, Wang Z, et al. Ferroptosis-inducing inorganic arsenic(II) sulfide nanocrystals enhance immune activation. Nano Res. 2023;16(7):9760–9767. doi: 10.1007/s12274-023-5617-y
   Web of Science ®Google Scholar
• Chen H, Ahn R, Van Den Bossche J, et al. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther. 2009;8(7):1955–1963. doi: 10.1158/1535-7163.MCT-09-0045
   PubMed Web of Science ®Google Scholar
• Chen H, Pazicni S, Krett NL, et al. Coencapsulation of arsenic‐ and platinum‐based drugs for targeted cancer treatment. Angew Chem Int Ed. 2009;48(49):9295–9299. doi: 10.1002/anie.200903655
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang X, Zhang J, et al. Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of c6 gliomas in rat brains. J Chemother. 2008;20(2):253–262. doi: 10.1179/joc.2008.20.2.253
   PubMed Web of Science ®Google Scholar
• Xu H, Li C, Wei Y, et al. Angiopep-2-modified calcium arsenite-loaded liposomes for targeted and pH-responsive delivery for anti-glioma therapy. Biochem Biophys Res Commun. 2021;551:14–20. doi: 10.1016/j.bbrc.2021.02.138
   PubMed Web of Science ®Google Scholar
• Li C, Zhang K, Liu A, et al. MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma. Int J Pharm. 2021;609:121209. doi: 10.1016/j.ijpharm.2021.121209
   PubMedGoogle Scholar
• Peng Y, Zhao Z, Liu T, et al. Smart human-serum-albumin–As 2 O 3 nanodrug with self-amplified folate receptor-targeting ability for chronic myeloid leukemia treatment. Angew Chem Int Ed Engl. 2017;56(36):10845–10849. doi: 10.1002/anie.201701366
   PubMed Web of Science ®Google Scholar
• Li T, Tan S, Li M, et al. Holographically activatable nanoprobe via Glutathione/Albumin‐mediated exponential signal amplification for High‐Contrast tumor imaging. Adv Mater. 2023;35(10):2209603. doi: 10.1002/adma.202209603
   Web of Science ®Google Scholar
• Zhai Y, Liu M, Yang T, et al. Self-activated arsenic manganite nanohybrids for visible and synergistic thermo/immuno-arsenotherapy. J Controlled Release. 2022;350:761–776. doi: 10.1016/j.jconrel.2022.08.054
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang W, He Y, et al. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat Nanotech. 2021;16(12):1413–1423. doi: 10.1038/s41565-021-00980-7
   PubMed Web of Science ®Google Scholar
• Song X, Wu J, Song W, et al. Thiolated chitosan nanoparticles for stable delivery and smart release of As2O3 for liver cancer through dual actions. Carbohydr Polym. 2023;303:120462. doi: 10.1016/j.carbpol.2022.120462
   PubMed Web of Science ®Google Scholar
• Shen X, Rao Y, Liu D, et al. Biocompatible cationic polypeptoids with antibacterial selectivity depending on hydrophobic carbon chain length. J Mater Chem B. 2023;11(25):5786–5793. doi: 10.1039/D3TB00643C
   PubMed Web of Science ®Google Scholar
• Akhtar A, Wang SX, Ghali L, et al. Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers. J Biomed Res. 2017;31(3):177–188. doi: 10.7555/JBR.31.20160059
   PubMed Web of Science ®Google Scholar
• Zhang Q, Vakili MR, Li X-F, et al. Polymeric micelles for GSH-triggered delivery of arsenic species to cancer cells. Biomaterials. 2014;35(25):7088–7100. doi: 10.1016/j.biomaterials.2014.04.072
   PubMed Web of Science ®Google Scholar
• Wang Z, Liu W, Xu H, et al. Preparation and in vitro studies of stealth PEGylated PLGA nanoparticles as carriers for arsenic trioxide. Chin J Chem Eng. 2007;15(6):795–801. doi: 10.1016/S1004-9541(08)60005-1
   Web of Science ®Google Scholar
• Ahn RW, Chen F, Chen H, et al. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clin Cancer Res. 2010;16(14):3607–3617. doi: 10.1158/1078-0432.CCR-10-0068
   PubMed Web of Science ®Google Scholar
• Gong F, Cheng X, Wang S, et al. Heparin-immobilized polymers as non-inflammatory and non-thrombogenic coating materials for arsenic trioxide eluting stents. Acta Biomater. 2010;6(2):534–546. doi: 10.1016/j.actbio.2009.07.013
   PubMed Web of Science ®Google Scholar
• Huang Y, Xu Z, Wei Y, et al. Albumin-embellished arsenic trioxide-loaded polymeric nanoparticles enhance tumor accumulation and anticancer efficacy via transcytosis for hepatocellular carcinoma therapy. AAPS Pharm Sci Tech. 2022;23(4):111. doi: 10.1208/s12249-022-02254-4
   PubMed Web of Science ®Google Scholar
• Song X, You J, Shao H, et al. Effects of surface modification of as 2 O 3 -loaded PLGA nanoparticles on its anti-liver cancer ability: An in vitro and in vivo study. Colloids Surf B Biointerfaces. 2018;169:289–297. doi: 10.1016/j.colsurfb.2018.05.024
   PubMed Web of Science ®Google Scholar
• Song X, Wang J, Xu Y, et al. Surface-modified PLGA nanoparticles with PEG/LA-chitosan for targeted delivery of arsenic trioxide for liver cancer treatment: Inhibition effects enhanced and side effects reduced. Colloids Surf B Biointerfaces. 2019;180:110–117. doi: 10.1016/j.colsurfb.2019.04.036
   PubMed Web of Science ®Google Scholar
• Qian C, Wang Y, Chen Y, et al. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials. 2013;34(26):6175–6184. doi: 10.1016/j.biomaterials.2013.04.056
   PubMed Web of Science ®Google Scholar
• Lu Y, Han S, Zheng H, et al. A novel RGDyC/PEG co-modified PAMAM dendrimer-loaded arsenic trioxide of glioma targeting delivery system. Int J Nanomedicine. 2018;13:5937–5952. doi: 10.2147/IJN.S175418
   PubMed Web of Science ®Google Scholar
• Lian Y, Wang X, Guo P, et al. Erythrocyte membrane-coated arsenic trioxide-loaded sodium alginate nanoparticles for tumor therapy. Pharmaceutics. 2019;12(1):21. doi: 10.3390/pharmaceutics12010021
   PubMed Web of Science ®Google Scholar
• Zou Y, Huang B, Cao L, et al. Tailored mesoporous inorganic biomaterials: assembly, functionalization, and drug delivery engineering. Adv Mater. 2021;33(2):2005215. doi: 10.1002/adma.202005215
   PubMed Web of Science ®Google Scholar
• Wu X, Han Z, Schur RM, et al. Targeted mesoporous silica nanoparticles delivering arsenic trioxide with environment sensitive drug release for effective treatment of triple negative breast cancer. ACS Biomater Sci Eng. 2016;2:501–507. doi: 10.1021/acsbiomaterials.5b00398
   PubMed Web of Science ®Google Scholar
• Ellison PA, Chen F, Goel S, et al. Intrinsic and stable conjugation of thiolated mesoporous silica nanoparticles with radioarsenic. ACS Appl Mater Interfaces. 2017;9(8):6772–6781. doi: 10.1021/acsami.6b14049
   PubMed Web of Science ®Google Scholar
• Jiang L, Wang X, Raza F, et al. PEG-grafted arsenic trioxide-loaded mesoporous silica nanoparticles endowed with pH-triggered delivery for liver cancer therapy. Biomater Sci. 2023;11(15):5301–5319. doi: 10.1039/D3BM00555K
   PubMed Web of Science ®Google Scholar
• Zhang B, Chen X, Fan X, et al. Lipid/PAA-coated mesoporous silica nanoparticles for dual-pH-responsive codelivery of arsenic trioxide/paclitaxel against breast cancer cells. Acta Pharmacol Sin. 2021;42(5):832–842. doi: 10.1038/s41401-021-00648-x
   PubMed Web of Science ®Google Scholar
• Wu Q, Chen X, Wang P, et al. Delivery of arsenic trioxide by multifunction nanoparticles to improve the treatment of hepatocellular carcinoma. ACS Appl Mater Interfaces. 2020;12(7):8016–8029. doi: 10.1021/acsami.9b22802
   PubMed Web of Science ®Google Scholar
• Ettlinger R, Sönksen M, Graf M, et al. Metal–organic framework nanoparticles for arsenic trioxide drug delivery. J Mater Chem B. 2018;6(40):6481–6489. doi: 10.1039/C8TB01899E
   PubMed Web of Science ®Google Scholar
• Ettlinger R, Moreno N, Volkmer D, et al. Zeolitic imidazolate framework‐8 as pH‐sensitive nanocarrier for “arsenic trioxide” drug delivery. Chem – Eur J. 2019;25(57):13189–13196. doi: 10.1002/chem.201902599
   PubMed Web of Science ®Google Scholar
• Schnabel J, Ettlinger R, Bunzen H. Zn‐MOF‐74 as pH‐responsive drug‐delivery system of arsenic trioxide. ChemNanomat. 2020;6(8):1229–1236. doi: 10.1002/cnma.202000221
   Web of Science ®Google Scholar